Statements Of Cash Flows (USD $)	9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012
Cash flows from operating activities
Net loss	$ (64,795,382)	$ (4,921,766)
Adjustments to reconcile net loss to cash used in operating activities:
Depreciation	705,717	989,501
Amortization	224,875	224,875
Amortization of deferred finance costs and debt discounts	7,702,681	1,978,264
Share-based compensation	670,873	1,979,159
Loss on asset disposal	16,886	4,122
Adjustment of warrants and convertible debt features	46,758,917	(9,679,848)
Interest due from issuance of stock	551,296
Changes in operating assets and liabilities:
Accounts receivable	3,474,806	594,397
Other receivables	52,522	17,910
Inventories	360,209	(693,139)
Prepaid expenses and other current assets	527,500	(279,595)
Other assets	(828)	1,648
Accounts payable	(362,872)	(1,033,514)
Accrued liabilities	1,477,987	(560,126)
Deferred revenue	(2,287,620)	(660,196)
Other liabilities		(3,093)
Net cash used in operating activities	(4,922,433)	(12,041,401)
Cash flows from investing activities
Purchase of equipment		(130,103)
Net cash used in investing activities		(130,103)
Cash flows from financing activities
Payments of term note	(4,000,000)	(3,000,000)
Proceeds from revolving line of credit	37,237,131	42,246,305
Payments of revolving line of credit	(41,490,148)	(49,363,204)
Proceeds from subordinated convertible debt, net of issuance costs		7,738,351
Proceeds from Healthcare Royalty Partners debt	2,500,000	2,500,000
Payments of Healthcare Royalty Partners debt	(263,192)	(1,114,095)
Proceeds from issuance of stock and warrants, net of issuance costs	11,547,529	9,122,431
Net cash provided by financing activities	5,531,320	8,129,788
Net decrease in cash and cash equivalents	608,887	(4,041,716)
Cash and cash equivalents at beginning of period	7,777,718	13,954,919
Cash and cash equivalents at end of period	$ 8,386,605	$ 9,913,203